A
BMY icon

AustralianSuper’s Bristol-Myers Squibb BMY Stock Holding History

AustralianSuper’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$140M Buy
2,433,354
+307,998
+14% +$17.7M 0.61% 42
2026
Q1 		$129M Sell
2,125,356
-209,324
-9% -$12.2M 0.67% 33
2025
Q4 		$126M Sell
2,334,680
-26,483
-1% -$1.27M 0.59% 37
2025
Q3 		$106M Sell
2,361,163
-871,756
-27% -$40.7M 0.5% 41
2025
Q2 		$150M Buy
3,232,919
+503,930
+18% +$24.7M 0.76% 28
2025
Q1 		$166M Sell
2,728,989
-213,391
-7% -$12.4M 0.94% 22
2024
Q4 		$166M Sell
2,942,380
-398,552
-12% -$22.3M 0.79% 28
2024
Q3 		$173M Sell
3,340,932
-516,629
-13% -$24.2M 0.86% 32
2024
Q2 		$160M Buy
3,857,561
+775,908
+25% +$34.7M 0.92% 32
2024
Q1 		$163M Buy
3,081,653
+1,386,762
+82% +$70.6M 0.96% 35
2023
Q4 		$87M Buy
+1,694,891
New +$89M 0.52% 56
2023
Q3 		– Sell
-25,432
Closed -$1.63M – 240
2023
Q2 		$1.63M Sell
25,432
-12,793
-33% -$858K 0.01% 214
2023
Q1 		$2.65M Sell
38,225
-1,153,158
-97% -$81.3M 0.02% 166
2022
Q4 		$86.1M Buy
1,191,383
+29,965
+3% +$2.26M 0.57% 49
2022
Q3 		$82.6M Sell
1,161,418
-397,929
-26% -$28.9M 0.59% 44
2022
Q2 		$120M Buy
1,559,347
+71,054
+5% +$5.41M 0.74% 36
2022
Q1 		$109M Sell
1,488,293
-338,678
-19% -$22.7M 0.59% 39
2021
Q4 		$114M Buy
1,826,971
+710,844
+64% +$41.7M 0.59% 43
2021
Q3 		$66M Buy
1,116,127
+190,988
+21% +$12.6M 0.42% 48
2021
Q2 		$61.8M Buy
925,139
+148,594
+19% +$9.69M 0.43% 47
2021
Q1 		$49M Sell
776,545
-1,960,945
-72% -$122M 0.38% 49
2020
Q4 		$170M Buy
2,737,490
+274,189
+11% +$16.9M 1.27% 36
2020
Q3 		$149M Buy
2,463,301
+1,321,614
+116% +$79.5M 1.27% 36
2020
Q2 		$67.1M Buy
1,141,687
+527,200
+86% +$31.5M 0.65% 45
2020
Q1 		$34.3M Buy
614,487
+304,086
+98% +$18.6M 0.44% 52
2019
Q4 		$19.9M Buy
310,401
+130,586
+73% +$7.48M 0.17% 79
2019
Q3 		$9.12M Buy
+179,815
New +$8.45M 0.09% 111

Other funds holding BMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

AustralianSuper's BMY Position: Q2 2026 in Review

AustralianSuper increased its Bristol-Myers Squibb (BMY) stake by 14% in Q2 2026, buying an estimated $17.7M and bringing the position to 2,433,354 shares worth $140M. The position accounts for 0.61% of the portfolio, ranked #42.

AustralianSuper first reported a position in BMY in Q3 2019 and has held it in 27 quarters since. The position peaked at $173M in Q3 2024. 2,508 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • AustralianSuper held 2,433,354 shares of Bristol-Myers Squibb worth $140M as of Q2 2026.
  • AustralianSuper bought 307,998 Bristol-Myers Squibb shares in Q2 2026, an estimated $17.7M.
  • Bristol-Myers Squibb made up 0.61% of AustralianSuper's portfolio in Q2 2026, its #42 holding.
  • AustralianSuper first reported a position in Bristol-Myers Squibb in Q3 2019 and has held it in 27 quarters since.
  • AustralianSuper's Bristol-Myers Squibb position peaked at $173M in Q3 2024.
  • 2,508 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on AustralianSuper's 13F filing for Q2 2026, filed 12 Aug 2026.